2019 Novel Coronavirus (COVID-19) With Influenza A, Influenza B and Respiratory Syncytial Virus, NAA

Also known as: 2019 Novel Coronavirus, COVID-19, Influenza, Respiratory Viral panel, SARS-CoV-2

Clinical Use

Order Test

Use

Results are for the identification and differentiation of RNA from SARS-CoV-2, Influenza A, Influenza B and RSV.

Special Instructions

Not provided.

Limitations

The assay is intended for use under the FDA's Emergency Use Authorization specifically for COVID-19 testing. For Influenza A+B and RSV, this test is developed by Labcorp and has not been cleared or approved by the FDA. Negative results do not rule out infection and should be interpreted in the context of the clinical presentation and medical history. Results are typically released electronically to speed up delivery, but delays may occur due to sample transport times and prioritization by healthcare authorities.

Test Details

Methodology

PCR-based (RT-PCR)

Biomarkers

4 targets

Influenza AInfluenza BRSVSARS-CoV-2

LOINC Codes

Order Codes

78922-2 - Resp path DNA+RNA Pnl Nph NAA+probe

Result Codes

94759-8 - SARS-CoV-2 RNA Nph Ql NAA+probe
76078-5 - FLUAV RNA Nph Ql NAA+probe
76080-1 - FLUBV RNA Nph Ql NAA+probe
76089-2 - RSV RNA Nph Ql NAA+probe

Result Turnaround Time

1-3 days

Specimen

Nasopharyngeal Swab

Volume

1 - 3 mL

Minimum Volume

1 mL

Container

Nasopharyngeal swab in VTM/UTM or 0.9% saline

Collection Instructions

Collect using standard techniques. Place the swab into VTM/UTM and cap tightly.

Storage Instructions

Frozen at -20° C (preferred). Refrigerated specimens and room temperature specimens (if received for testing within 72 hours of collection) are also acceptable.

Causes for Rejection

Unacceptable specimens include those that are beyond the established stability, improperly labeled, grossly contaminated, broken or with significant leakage in transit or improperly collected or shipped. Inhibitory substances like heparin and high concentrations of EDTA should not be used.